AZTA Share Price Performance
US$28.18
-18.71 (-39.90%)
27.1% undervalued intrinsic discount
US$38.67
Fair Value
Price US$28.18
AnalystConsensusTarget US$38.67
AnalystHighTarget US$45.00
AnalystLowTarget US$30.00
Fair ValueUS$38.67
Share Pricen/a
Azenta, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
AZTA Community Narratives
AN
Fair Value US$38.67 27.1% undervalued intrinsic discount
AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$45 37.4% undervalued intrinsic discount
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$30 6.1% undervalued intrinsic discount
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$30
6.1% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
5.79% p.a.
Profit Margin
4.87%
Future PE
51.44x
Price in 2029
US$37.61
AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026
Key Takeaways Strong growth driven by personalized medicine, automation, and outsourcing trends, with recurring revenue and margin expansion from stable pricing and digital modernization. Operational efficiency, strategic investments, and disciplined portfolio management are fueling both cost control and sustainable long-term earnings resilience.Read more
85
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$38.67
27.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
5.76% p.a.
Profit Margin
5.69%
Future PE
55.71x
Price in 2029
US$47.53
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$45
37.4% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
6.71% p.a.
Profit Margin
6.78%
Future PE
54.34x
Price in 2029
US$56.76
Trending Discussion
Recently Updated Narratives
AN
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
Fair Value: US$30 6.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside
Fair Value: US$38.67 27.1% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
Fair Value: US$45 37.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Azenta, Inc. Key Details
About AZTA
- Founded
- 1978
- Employees
- 3000
- CEO
- WebsiteView website
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
